Technology Overview

The cytokine IL-1beta plays a key role in the systemic inflammation characteristic of autoimmune diseases such as Inflammatory bowel disease, multiple sclerosis and type I diabetes. Controlling this type of inflammation has been challenging because IL-1beta also plays a vital role in responding to infectious diseases. Researchers at Cincinnati Children's have identified a novel cross-talk mechanism—independent of the immune response to invading pathogens—that can be targeted to reduce IL-1beta production during autoimmune inflammation without diminishing the immune response to foreign invaders.

Applications

Inflammation cytokine storms induced by CAR T cell therapy or Immune checkpoint therapy induced adverse events.

Autoimmune diseases like Inflammatory bowel disease, multiple sclerosis and type I diabetes

Advantages

Unlike other innovations in this field, this research targets a novel mechanism that reduces the production of IL-1beta, mitigating damaging inflammation without reducing antimicrobial immune response.

Market Overview

Autoimmune diseases such as Inflammatory bowel disease, Multiple Sclerosis and Type I Diabetes affect more than 3000 million people worldwide.

Global therapeutics market for autoimmune diseases was $54 billion (2021)

Inflammation is a driver of many autoimmune disease disorders

Investigator Overview

Chandrashekhar Pasare, DVM, PhD Professor and Division Director, Division of Immunobiology